An Anti–Trop-2 Antibody–Drug Conjugate for Triple-Negative Breast Cancer

The treatment of patients with triple-negative breast cancer (TNBC) — defined as ER-negative, PR-negative, and HER2-negative disease — remains a therapeutic challenge, with chemotherapy continuing to be the standard of care. Numerous strategies are under intense investigation, including immune therapy and targeted therapies, the latter addressing driver mutations detected in TNBC. To date, finding the “next trastuzumab” for TNBC remains aspirational.

Investigators have now conducted an industry-sponsored, multicenter, single-arm study in this setting of sacituzumab govitecan (SG), an antibody–drug conjugate that targets Trop-2, a 46-kD glycoprotein that is overexpressed in many epithelial tumors, particularly in TNBC; Trop-2 overexpression h…